Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Untargeted plasma metabolomics identifies endogenous metabolite with drug-like properties in chronic animal model of multiple sclerosis.
Fingolimod is a potential novel therapy for multiple sclerosis.
The Vitamin D to Ameliorate Multiple Sclerosis (VIDAMS) trial: study design for a multicenter, randomized, double-blind controlled trial of vitamin D in multiple sclerosis.
New Tysabri data reaffirm substantial efficacy in treatment of people with MS and demonstrate stability of anti-JCV antibody status
FDA Accepts Filing of BETACONNECT™* for Relapsing-Remitting Multiple Sclerosis Patients Taking BETASERON® (interferon beta-1b)
Background information on multiple sclerosis patients stopping ongoing immunomodulatory therapy: a multicenter study in a community-based environment.
Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: A multi-center, retrospective analysis.
Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects.
CHMP adopts positive opinion for PLEGRIDY™ (peginterferon beta-1a) as a treatment for multiple sclerosis in the European Union
Teaching NeuroImages: MRI in advanced neuromyelitis optica.
Chemistry, toxicology, pharmacology and pharmacokinetics of idebenone: a review.
Gustatory Dysfunction in Multiple Sclerosis
FTY720/Fingolimod, a Sphingosine Analogue, Reduces Amyloid-β Production in Neurons.
Acorda Therapeutics announces issuance of additional U.S. Patent for AMPYRA® covering a range of dosage strengths
Astaxanthin as a Potential Neuroprotective Agent for Neurological Diseases.
Laquinimod Phase IIa Study in Active Crohn's Disease
Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.
Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis.
Repurposing the NRF2 activator dimethyl fumarate as therapy against synucleinopathy in Parkinson's disease.
Ofatumumab Dose-finding in RRMS Patients
The role of alemtuzumab in facilitating maintenance immunosuppression minimization following solid organ transplantation.
Study to evaluate early glatiramer acetate treatment in delaying conversion to CDMS of subjects presenting with CIS (PreCISe)
Better Prognosis of Multiple Sclerosis in Patients Who Experienced a Full-Term Pregnancy.
Glatiramer acetate treatment negatively regulates type I interferon signaling.
BRIEF-Health Canada approves Genzyme's Aubagio to treat relapsing remitting multiple sclerosis

Pages